Chiesi Farmaceutici SpA has identified tyrosine-protein kinase JAK1 and/or JAK2 and/or JAK3 and/or TYK2 inhibitors reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.

Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.

Nutshell Biotech (Shanghai) Co. Ltd. has discovered fibroblast growth factor receptor (FGFR) inhibitors reported to be useful for the treatment of cancer.

Dicot AB reports that LIB-01 has shown a...

Nimbus Therapeutics LLC has entered into a...

Atyr Pharma Inc. has entered into a research...

Researchers from the Barcelona Institute of...